Table 2.

Outcome and covariate data extracted during chart reviews

Week one	Twelve weeks follow-up
Tumour site	Delivered radiotherapy dose, fractionation, start date, finish date and total treatment time
Tumour stage	Treatment interruption
Concurrent chemotherapy	Unplanned hospital visits and length of stay
Concurrent surgery	Tumour response
Proposed RT dose, fractionation and treatment time	Whether PHQ-2 follow-up was documented
Prophylactic PEG/nasogastric tube feeding placement and date inserted	Number and frequency of dietetic consults
Whether PHQ-2 screening was documented	Whether PG-SGA/formal nutritional assessment was documented in the final week of treatment and the score
Whether PG-SGA/formal nutritional assessment was documented in the first week of treatment and the score	Complications with PEG/date of removal of PEG if removed
	Whether a PEG or nasogastric tube feeding was used for alimentation during treatment or post treatment and date inserted and removed
	The dates and dosage of all medications/treatments received as part of another clinical trial

PEG, Percutaneous endoscopic gastrostomy; PG-SGA, Patient Generated Subjective Global Assessment; PHQ-2, The Patient Health Questionnaire 2; RT, radiotherapy.